R&D News | pharmaphorum

News

Trial of Bundibugyo Ebola drugs starts in DRC

Patients are now being enrolled in a trial of two potential therapies for Bundibugyo Ebola, Mapp's MBP134 and Gilead's remdesivir, says WHO.

News

Respiratory biotech Celea raises $180m, and other financings

This week's collection of venture capital financings in the biotech arena includes rounds for Celea, Beeline, Flare, Lycia, and Telum.

News

Newron charts course forward for stalled schizophrenia drug

Newron thinks it may have reached an agreement with the FDA on a way to get the US development of its schizophrenia candidate evenamide back on track.

News

AZ forges ever-closer ties with China's CSPC Pharma

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

News

Ipsen's M&A team strikes again, adding Memo in $700m deal

Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.

Trial of Bundibugyo Ebola drugs starts in DRC

Respiratory biotech Celea raises $180m, and other financings

Newron charts course forward for stalled schizophrenia drug

AZ forges ever-closer ties with China's CSPC Pharma

Roche's KRAS drug tops its rivals in lung cancer trial

Ipsen's M&A team strikes again, adding Memo in $700m deal

ESMO26: Lowering toxicity, extending lives, with Syncromune

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks